Risk of Autism After Prenatal Topiramate, Valproate, or Lamotrigine Exposure
( N Engl J Med . 2024;390(12):1069-1079. DOI: 10.1056/NEJMoa2309359) Maternal use of valproate during pregnancy has been linked to a heightened risk of neurodevelopmental disorders in children. While most studies on other antiseizure medications did not show increased risks of these disorders, insufficient and inconsistent data exist regarding the risk of autism spectrum disorder (ASD) associated with maternal topiramate use. A study conducted on maternal use of antiseizure medications during pregnancy, particularly focusing on the risk of ASD in children, revealed noteworthy findings.
Authors
- Kathryn J. Gray (ORCID: https://orcid.org/0000-0002-3541-3724)
- Sonia Hernández–Dı́az (ORCID: https://orcid.org/0000-0003-1458-7642)
- B. Lester (ORCID: https://orcid.org/0000-0002-6151-0288)
- Loreen Straub (ORCID: https://orcid.org/0000-0003-2623-2726)
- KF Huybrechts
- McDougle Cj
- Helen Mogun
- B.T. Bateman
- Katherine L. Wisner (ORCID: https://orcid.org/0000-0003-3458-5986)
- Elyse DiCesare
- Yimin Zhu
- PB Pennell
Institutions
- Harvard University (US)
Publication Details
- Journal
- Obstetric Anesthesia Digest
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1097/01.aoa.0001026636.29990.84
- Primary Topic
- Pharmacological Effects and Toxicity Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00